Home
HelpTest Code GFAPP Glial Fibrillary Acidic Protein (GFAP), Plasma
Shipping Instructions
Send refrigerated.
Specimen Required
Patient Preparation:
Fasting: 8 hours, required
Supplies: Sarstedt Aliquot Tube, 5 mL (T914)
Collection Container/Tube: Lavender top (EDTA)
Submission Container/Tube: Plastic vial
Specimen Volume: 1 mL plasma
Collection Information: Centrifuge and aliquot plasma into a plastic vial.
Useful For
As a biomarker of astrocyte activation related to brain injury and various neurological disorders
Method Name
Chemiluminescent Enzyme Immunoassay (CLEIA)
Reporting Name
Glial Fibrillary Acidic Protein, PSpecimen Type
EDTA PlasmaSpecimen Minimum Volume
Plasma: 0.75 mL
Specimen Stability Information
| Specimen Type | Temperature | Time |
|---|---|---|
| EDTA Plasma | Refrigerated (preferred) | 14 days |
| Frozen | 90 days | |
| Ambient | 72 hours |
Reference Values
<40 years: ≤32.6 pg/mL
40-49 years: ≤50.5 pg/mL
50-59 years: ≤67.5 pg/mL
60-69 years: ≤90.3 pg/mL
≥ 70 years: ≤120.8 pg/mL
Interpretation
Increased glial fibrillary acidic protein (GFAP) concentrations have been observed during brain injury and in various neurological disorders. Currently, there are no disease-specific thresholds for interpretation; thus, results should be assessed according to established reference intervals. Some potential uses of GFAP are described below.
In traumatic brain injury (TBI), GFAP concentrations are increased in patients following mild to moderate TBI, and it may predict an unfavorable outcome.(1) GFAP has been shown to be detectable within one hour of injury, continues to rise and appears to peak within 20 to 24 hours, and then declines over 72 hours with a biological half-life of 24 to 48 hours.(2,3)
Glial fibrillary acidic protein concentrations have been reported to be higher in individuals with multiple sclerosis (MS) compared to healthy controls and individuals with non-inflammatory neurological disease.(4,5) Plasma GFAP concentrations have been shown to correlate with the severity of disability in patients with MS.(4,5)
In stroke, blood GFAP may be indicative of microglial injury as a result of intracerebral hemorrhage in individuals presenting with acute stroke symptoms. In this context, GFAP concentrations were higher in individuals with intracerebral hemorrhage than in patients with ischemic stroke.(6)
Increased blood GFAP concentrations have been detected in individuals with Alzheimer disease (AD), with rising levels observed at the preclinical phase of the disease.(7) Higher GFAP concentrations have been associated with an increased risk for future progression to dementia and a steeper cognitive decline.(8) In individuals with mild cognitive impairment, GFAP concentrations have been reported to predict future conversion to AD dementia.(7)
In individuals with autoimmune glial fibrillary acidic protein astrocytopathy (GFAP-A), an antibody-related astrocytic disease for which a specific GFAP antibody serves as a biological marker, elevations of plasma GFAP may be observed.(9) However, measurement of plasma GFAP is not recommended as part of the diagnostic evaluation for this rare autoimmune disease. In this context, measurement of GFAP-IgG antibodies in cerebrospinal fluid is recommended for the evaluation of individuals suspected of having GFAP-A.
Clinical Reference
1. Abdelhak A, Foschi M, Abu-Rumeileh S, et al. Blood GFAP as an emerging biomarker in brain and spinal cord disorders. Nat Rev Neurol. 2022;18(3):158-172
2. Papa L, Brophy GM, Welch RD, et al. Time course and diagnostic accuracy of glial and neuronal blood biomarkers GFAP and UCH-L1 in a large cohort of trauma patients with and without mild traumatic brain injury. JAMA Neurol. 2016;73(5):551-560
3. Thelin EP, Zeiler FA, Ercole A, et al. Serial sampling of serum protein biomarkers for monitoring human traumatic brain injury dynamics: A systematic review. Front Neurol. 2017;8:300
4. Hogel H, Rissanen E, Barro C, et al. Serum glial fibrillary acidic protein correlates with multiple sclerosis disease severity. Mult Scler. 2020;26(2):210-219
5. Ayrignac X, Le Bars E, Duflos C, et al. Serum GFAP in multiple sclerosis: correlation with disease type and MRI markers of disease severity. Sci Rep. 2020;10(1):10923
6. Foerch C, Curdt I, Yan B, et al. Serum glial fibrillary acidic protein as a biomarker for intracerebral haemorrhage in patients with acute stroke. J Neurol Neurosurg Psychiatry. 2006;77(2):181-184
7. Oeckl P, Halbgebauer S, Anderl-Straub S, et al. Glial fibrillary acidic protein in serum is increased in Alzheimer’s disease and correlates with cognitive impairment. J Alzheimers Dis. 2019;67(2):481-488. doi:10.3233/JAD-180325
8. Cicognola C, Janelidze S, Hertze J, et al. Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment. Alzheimers Res Ther. 2021;13(1):68. Published 2021 Mar 27. doi:10.1186/s13195-021-00804-9
9. Huang J, Huang W, Zhou R, Lin W, Chen T, Long Y. Detection and significance of glial fibrillary acidic protein antibody in autoimmune astocytopathy and related diseases. Ann Transl Med. 2023;11(7):288. doi:10.21037/atm-19-330
Day(s) Performed
Wednesday
Report Available
1 to 9 daysPerforming Laboratory
Mayo Clinic Laboratories in Rochester
Test Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
83520
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| GFAPP | Glial Fibrillary Acidic Protein, P | 97604-3 |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| GFAPP | Glial Fibrillary Acidic Protein, P | 97604-3 |